ME Therapeutics updates in vivo CAR and therapeutic mRNA STING programs
ME Therapeutics said it is providing a comprehensive update on its in vivo CD19/CD22 CAR program and its therapeutic mRNA STING program efforts.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.